3月28日(木) 14:30〜16:30 C会場 パシフィコ横浜 会議ホール3F 302 JK キナーゼ阻害薬開発の現状と展望 Drug Discovery & Development of Kinase Inhibitor オーガナイザー：宮田 直樹 JK-1 Design and Synthesis of Biologically Active Kinase Inhibitors through Rational Design Design and Synthesis of Biologically Active Kinase Inhibitors through Rational Design シンポジスト ： ○HONG Sungwoo JK-2 Development of kinase inhibitors in non-oncology indications Development of kinase inhibitors in non-oncology indications シンポジスト ： ○澤 匡明 JK-3 Development of Protein Kinase Inhibitors as Anticaner agent & Therapeutics for Neurodegenerative Diseases Development of Protein Kinase Inhibitors as Anticaner agent & Therapeutics for Neurodegenerative Diseases シンポジスト ： ○HAH Jung-Mi JK-4 Drug development and translational science of multiple receptor tyrosine kinase inhibitor (RTKI) lenvatinib (E7080) as an anti-cancer agent Drug development and translational science of multiple receptor tyrosine kinase inhibitor (RTKI) lenvatinib (E7080) as an anti-cancer agent シンポジスト ： ○船橋 泰博 検索ページに戻る
